Literature DB >> 2891946

Urogastrone/epidermal growth factor in treatment of congenital microvillous atrophy.

B Drumm, E Cutz, K B Tomkins, D Cook, J R Hamilton, P Sherman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2891946     DOI： 10.1016/s0140-6736(88)90303-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  Effects of longterm epidermal growth factor treatment on the normal rat colon.

Authors:  P Kissmeyer-Nielsen; L Vinter-Jensen; M Smerup
Journal:  Gut       Date:  1996-04       Impact factor: 23.059

2.  The value of proximal small intestinal biopsy in the differential diagnosis of chronic diarrhoea.

Authors:  A G Thomas; A D Phillips; J A Walker-Smith
Journal:  Arch Dis Child       Date:  1992-06       Impact factor: 3.791

3.  Potency and stability of C terminal truncated human epidermal growth factor.

Authors:  D P Calnan; A Fagbemi; J Berlanga-Acosta; T Marchbank; T Sizer; K Lakhoo; A D Edwards; R J Playford
Journal:  Gut       Date:  2000-11       Impact factor: 23.059

4.  Clinical response to the long acting somatostatin analogue SMS 201-995 in a child with congenital microvillus atrophy.

Authors:  R T Couper; A Berzen; G Berall; P M Sherman
Journal:  Gut       Date:  1989-07       Impact factor: 23.059

Review 5.  Epidermal growth factor in clinical practice - a review of its biological actions, clinical indications and safety implications.

Authors:  Jorge Berlanga-Acosta; Jorge Gavilondo-Cowley; Pedro López-Saura; Tania González-López; María D Castro-Santana; Ernesto López-Mola; Gerardo Guillén-Nieto; Luis Herrera-Martinez
Journal:  Int Wound J       Date:  2009-10       Impact factor: 3.315
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.